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Abstract: Nasal drug delivery is still primarily associated with locally-effective drugs, but next-
generation products utilising the benefits of nasal administration—such as easy access to a relatively
permeable mucosa, the presence of immunocompetent cells, and a direct route to the brain—are
under investigation. Nasal powders offer the potential to improve the drugs’ effects by providing
higher resistance against the mucociliary clearance, and thus prolonging the contact time of the drug
with its target site. However, suitable and easy-to-use in-vitro setups tailored to the characterisation
of this effect are missing. In this study, a selection of excipients for powder formulations were used
to evaluate the applicability of different methods which investigate the influence on the contact
time. The combination of the assessment of rheological properties, dynamic vapour sorption, and
adhesiveness on agar–mucin plates was found to be a valuable predictive tool. For the additional
assessment of the sensations associated with the close contact of powders and the mucosa, a slug
mucosal irritation assay was conducted and adapted to powders. These methods are regarded as
being especially useful for comparative screenings in early formulation development.
Keywords: nasal drug delivery; mucoadhesion; rheology; slug mucosal irritation assay
1. Introduction
Nasal drug administration is attractive, not only for the treatment of local diseases,
but also for systemic delivery, the needle-free application of peptides, and the targeting
of the central nervous system [1,2]. The rising awareness about nasal products will lead
to a higher number of challenging drug candidates in product development, requiring
formulations that are more sophisticated than the common liquid sprays or drops which
strongly dominate the market nowadays. The first powder formulations that entered the
marked were locally-acting products against hay fever (Teijin Rhinocort, beclomethasone
dipropionate, Teijin, Japan in 1986 and Erizas, dexamethasone cipecilate, Nippon Shnyaku,
Japan in 2012), and are commercially available in Japan. In 2016, Onzetra Xsail (sumatriptan;
Currax Pharmaceuticals, Morristown, NJ, USA) was the first nasal powder formulation
for systemic action approved by the food and drug administration (FDA), followed by
Baqsimi (glucagon, Eli Lilly, Indianapolis, IN, USA) in 2019. These two approvals within
the last five years may show a future trend, because powder formulations serve some
unmet needs in nasal drug delivery. They show a higher stability, allow the administration
of higher drug doses, and have been found to enhance the bioavailability in comparison to
liquids [3–8].
A key challenge that can be addressed through the use of powder formulations is the
limited residence time of drug substances in the nose due to mucociliary clearance [9,10].
As a physiological cleaning mechanism, the beating of the nasal cilia leads the upper
gel-like mucus layer, which covers the epithelium, to move with a velocity of 6 mm/min
towards the nasopharynx and throat [11]. Hence, drug particles from conventional liquid
Pharmaceutics 2021, 13, 385. https://doi.org/10.3390/pharmaceutics13030385 https://www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2021, 13, 385 2 of 14
formulations, after being deposited on the mucus surface, are removed from the nasal
cavity in about 15 min. Powder particles have shown higher resistance against the ciliary
beat [8]. This effect may be tailored by the specific use of excipients. Useful excipients in
nasal powder formulations would be soluble or insoluble fillers, mucoadhesive agents,
or adsorption enhancers including enzyme inhibitors [3], among which mucoadhesive
polymers appear to have the greatest potential to prolong the residence time in the nose.
When polymer particles come into contact with nasal mucus, the polymer chains hydrate,
while the surrounding mucosa dehydrates. Furthermore, hydrated polymers may entangle
with the mucin of the mucus layer. The resulting close contact of the particles with the
mucosa, specific interactions with mucin, and the change in mucus rheology prolong the
nasal residence time.
However, suitable in-vitro setups for powders, tailored to the characterisation of this
effect, are missing. While the applicable FDA guidance for industry explicitly does not
include nasal powders [12], they are included into the guideline on the pharmaceutical
quality of inhalation and nasal products of the European Medicines Agency (EMA) [13].
Both regulatory agencies focus in their recommendations on physical characterisation, the
assessment of particle size distribution, the uniformity of the delivered dose, and stability
issues. These tests are irremissible for the safe and effective use of nasal drug products, but
are not sufficient for the development and screening of new and sophisticated formulations.
Complementary experiments, which are useful for the evaluation of the behaviour of the
formulation in the nasal cavity, are comprehensively summarised in [14]. However, when
a reproducible screening method for the evaluation of powders is sought, most methods
prove to have limited applicability. Models that use nasal tissues are often described [15,16],
but inter-individual differences may limit the comparability of the obtained results. Because
liquids are still more prominent in nasal drug delivery than powders, most experiments
were mainly adjusted for the characterisation of liquids until now. When mucoadhesiveness
is evaluated using rheological measurements, solutions of the ingredients are generally
used [17,18]. Transferring such data to powders is difficult, because the process of swelling
which would occur in the nose is not represented. Another method that is used to assess
mucoadhesive potential is the evaluation of the dripping of a formulation onto a vertical
positioned plate covered with simulated nasal secretions [19]. While this method generated
reproducible results for liquids, and thus may be assumed to be suitable screening method,
the setup may bring difficulties for powders, because dripping can only be observed
after liquefaction, which requires an adequate surrounding that allows the hydration of
the sample.
Hence, the aim of this study was to provide a convenient set of methods and to
evaluate their applicability for powder formulations. Therefore, a selection of excipients,
containing fillers and mucoadhesive agents with different qualities, was investigated with
regard to their rheological behaviour in simulated nasal fluid, water vapour sorption, and
adhesiveness on agar–mucin gels. The methods facilitate the screening and comparison of
powder ingredients with regard to their suitability to affect nasal residence time. They can
therefore be considered particularly valuable for formulation development.
A second point, which is often underestimated, is the evaluation of sensory effects
coming along with nasal drug delivery [20]. Irritation, sneezing, itching, or pain caused
by the contact of powder particles with the highly-sensitive mucosa are difficult to assess
in animal studies or in vitro setups. Lenoir et al. provided a tool for the prediction of
such sensations on human mucosa, which is the slug mucosa irritation (SMI) assay. A
correlation was demonstrated between an increase in mucus production in slugs and an
elevated incidence of stinging, itching, and burning sensations in humans [21]. However,
the test was so far only used for liquid formulations, so the second aim of this study was to
evaluate the SMI assay as predictive tool for nasal powders.
The availability of appropriate characterisation and screening capabilities will be key
for the optimisation of nasal powder formulations in the future.
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2. Materials and Methods
2.1. Materials
Nine different mucoadhesive polymers and four different fillers were selected for this
study. Substances with different properties regarding their interaction potential with mucus
(solubility, charge), were used to investigate the respective effect in nasal drug delivery.
As mucoadhesive agents, the neutral polymers hydroxypropyl methyl cellulose
(HPMC 400 and 4000, Shin-Etsu, Chiyoda, Japan), hydroxypropyl cellulose (HPC (G)/(M))
and hydroxyethyl cellulose (HEC (G)/(M) (both: Ashland, Covington, KY, USA; G: declared
viscosity of a 2% solution (25 ◦C) 150–400 mPas; M: declared viscosity of a 2% solution
(25 ◦C) 4000–6500 mPas), the amphoteric and soluble chitosan derivative carboxymethyl
chitosan (Heppe medical Chitosan GmbH, Halle, Germany) and the anionic polymers
sodium carboxymethyl cellulose (CMC, Sigma-Aldrich, Saint Louis, MO, USA, medium
viscosity) and low-methoxyl (LM) pectin (Herbstreith & Fox, Werder, Germany) were used.
Mannitol (Pearlitol 160C, Roquette, Lestrem, France) and lactose (Inhalac 230, Meggle,
Wasserburg am Inn, Germany) were selected as the soluble fillers, and microcrystalline
cellulose (MCC, Vivapur 102, JRS Pharma, Rosenberg, Germany) and colloidal MCC (Vi-
vapur MCG 811 P, JRS Pharma, Rosenberg, Germany) were used as the insoluble fillers.
The selection criterion for all of the substances was non-toxicity. Therefore, excipients
were chosen that are included in the inactive ingredient database of the FDA for nasal or
respiratory use (HPMC, HEC, Pectin, CMC, mannitol, lactose, MCC), are used in marked
products in Europe (HPC), or are reported to be non-toxic in the literature (chitosan and
derivates [22,23]).
The porcine stomach mucin type II was purchased from Sigma-Aldrich (Saint Louis,
MO, USA).
2.2. Preparation of the Powder Samples
For better comparison, sieve fractions of the raw materials were used in the experi-
ments. In order to ensure successful deposition in the nose, particle sizes between 10 µm
and 150 µm are needed in nasal drug delivery [24]; thus, analytical sieves with mesh sizes
of 32 µm, 90 µm and 150 µm were used to classify the raw materials. The substances were
sieved on a laboratory sieve shaker (Retsch GmbH & Co. KG, Germany), and fractions of
32–90 µm, 90–150 µm, and 32–150 µm were obtained. The characteristics of the excipients
are summarised in Table 1.
Table 1. Characteristics of the excipients selected for this study.
Mucoadhesive Agent Viscosity Grade Charge
x50 of Sieve Fractions ± SD, µm
32–90 µm 90–150 µm 32–150 µm
HPMC (hydroxypropyl
methyl cellulose)
400 (2%, 20 ◦C)
neutral
72.6 ± 1.3 141.6 ± 0.8 99.7 ± 1.6
4000 (2%, 20 ◦C) 74.8 ± 1.0 139.5 ± 0.5 86.5 ± 0.7
HPC (hydroxypropyl
cellulose)
G * 96.6 ± 1.0 179.8 ± 14.7 136.8 ± 9.2
M ** 92.1 ± 0.4 163.1 ± 0.7 131.4 ± 6.9
HEC (hydroxyethyl cellulose) G * 64.7 ± 0.1 134.6 ± 1.5 78.9 ± 0.6
M ** 73.4 ± 1.6 140.3 ± 2.8 88.7 ± 0.5
CMC (carboxymethyl cellulose) medium
anionic
74.6 ± 0.5 138.9 ± 4.4 95. 2 ± 1.9
Pectin N/A 78.4 ± 0.6 133.0 ± 1.1 95.8 ± 5.4
Carboxymethyl Chitosan N/A amphoteric 65.8 ± 1.9 162.4 ± 1.1 142.4 ± 2.4
Filler Solubility in Water
x50 of Sieve Fractions ± SD [µm]
32–90 µm 90–150 µm 32–150 µm
Mannitol
soluble
65.4 ± 0.1 160.3 ± 0.4 113.5 ± 2.0
Lactose N/A N/A 100.8 ± 0.5
MCC (microcrystalline cellulose)
insoluble
N/A N/A 88.0 ± 0.5
colloidal MCC N/A N/A 70.7 ± 2.6
* G: declared viscosity of a 2% solution (25 ◦C) 150–400 mPas. ** M: declared viscosity of a 2% solution (25 ◦C) 4000–6500 mPas.
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2.3. Determination of the Particle Size Distribution
The particle size distribution was determined by laser diffraction using a HELOS laser
diffractometer (Sympatec GmbH, Germany) equipped with a RODOS dispersing system.
The particles were dispersed with a dispersing pressure of 3 bar. The data was analysed
according to the Fraunhofer theory. All of the measurements were performed in triplicate.
2.4. Evaluation of the Influence of the Powders on the Nasal Residence Time
2.4.1. Rheological Testing
The rheological measurements were conducted using a plate-to-plate rheometer with
a plate diameter of 40 mm (CVO 120 HRNF, Bohlin Instruments, Germany). The samples
were prepared by adding 30 mg of sieved powder to 1.5 mL of simulated nasal fluid (SNF,
Table 2) [25] and vortexed for 20 s. The dispersions were allowed to rest for 1 min, or for
15 min before measurement, in order to model the conditions directly after the application
to the nose, and at the end of the residence time with a physiological clearance rate. The
measurements were conducted at the nasal temperature of 32 ◦C [26].
The steady-shear viscosity was measured at a constant shear rate of 1 Hz, which is the
effective shear rate in nasal mucus. This shear rate results from the directional movement
of the cilia of the nasal epithelium, which has a beating frequency of 10 Hz [27].
The viscoelastic behaviour was assessed by oscillation measurements. The frequency-
dependent elastic (G′) and viscous (G”) moduli were recorded at a constant deformation of
0.02, which lies in the linear viscoelastic region of all of the samples. The dissipation factor
was calculated according to Equation (1):
tan δ = G”/G′. (1)





CaCl2 × 2 H2O 0.32 g/L
double-distilled water q.s.
2.4.2. Adhesiveness on Agar–Mucin Gels
The mucoadhesive potential of the polymer samples was assessed by measuring the
displacement of powder on agar–mucin and pure agar gels on an inclined plane. The
method was adapted from Bertram and Bodmeier [28]. A hot solution of 1.5% agar with or
without 2% mucin in phosphate buffer, pH 6.4 (Ph. Eur.), was cast on a petri dish (diameter
14 cm) and left for gelation in a refrigerator overnight. Prior to the test, the gels were stored
for 1 h at a temperature of 32 ◦C in order to equilibrate to the test conditions. In total,
25 mg of powder (sieve fraction 32–150 µm) was placed on top of the gel in a spot with a
diameter of approximately 10 mm. In order to start the test, the petri dishes were placed
in an upright position with an angle of 45◦, and the displacement of the powder samples
was measured as a function of time. In order to assess the interaction of the mucoadhesive
polymers with mucin, the test was conducted on agar–mucin and pure agar gels, and the
difference in displacement was evaluated. The experimental setup is shown in Figure 1. All
of the measurements were conducted in triplicate. The maximal measurable displacement
on the plates was 10 cm. The displacements that exceeded this mark are listed as >10 cm.
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Figure 1. Schematic illustration of the experimental setup.
2.4.3. Dynamic Vapour Sorption (DVS)
The water vapour sorption of the substances (sieve fraction 32–150 µm) was deter-
mined using a DVS Resolution (Surface Measurement Systems Ltd., London, UK). The
relative humidity was increased and decreased stepwise from 0% to 90% to 0% in isother-
mal conditions (25 ◦C). This program was conducted twice. Each step was held until mass
equilibrium was reached. Hygroscopicity can be assessed by using the criteria from Ph.
Eur. 10.0/5.11.00.00, which rate the gain in mass at 80% relative humidity and 25 ◦C. A
mass gain of 0.2–2% is classified as slightly hygroscopic, a mass gain of 2–15% is classified
as hygroscopic, and a mass gain of 15% and higher is classified as very hygroscopic.
2.5. Evaluation of the Sensory Effects in the Nose
Slug Mucosal Irritation Assay
In order to assess the potential of the powder samples for stinging, itching, and
burning sensations in humans, the method of Lenoir et al. was adapted and tested for
powder formul tion [29]. The test is based on the asses men of the amount of mucus
produced by lugs of the species Arion lusitanicus, which are placed in contact with the
sample, as a measure for the extent of the sensory effects in the n se. In [21], a correlation
etween the nasal discomfort, reported by participants of a human nose irritation test
after the use of liquid formulations, and the mean total mucus production of the slugs
was found. Hence, the assay may serve as surrogate for clinical trials in the screening of
nasal formulations.
The slugs for the experiments were obtained by wild harvesting, and were kept under
laboratory conditions. Two days prior to the experiment, slugs with a body weight between
3 g and 6 g were isolated (placed on paper towels moistened with phosphate buffered
saline pH 7.4, PBS, Table 3) and their body wall was daily wetted with 1 mL of PBS and
checked for any mucosal damages.
The samples were prepared and placed into petri dishes. As described in [29], 100 µL
PBS was used as the negative control (no irritation) and 100 µL of a 1% (w/v) benzalkonium
chloride solution was used as positive control (maximum irritation). Because PBS, as the
negative control, leads to a weight gain of slugs due to hydration, the test was also
conducted without sample as a negative control, because hydration can only occur with
liquid but not with powder samples. The sample amount for the powders was adapted
to 50 mg in order to display a proper dose for nasal powder administration. For all of
the powder samples, a sieve fraction of 32 µm–150 µm was used. For the mannitol, sieve
fractions of 32 µm–90 µm and 90 µm–50 µm were tested additionally, in order to investigate
the influence of particle size.
At the beginning of the experiment, the slugs and the petri dishes containing the
samples were weighed. Subsequently, the slugs were placed on the test substances for a
contact period (CP) of 15 min. After the contact period, the slugs were transferred to petri
dishes with 1.5 mL PBS for a resting period of 60 min, and the petri dishes containing the
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test substances and the produced mucus of the slugs were re-weighed. This procedure was
repeated two times, so that a total mucus production out of three contact periods could be
calculated. The results were displayed as the total mucus production (TM) in percent of







M(Mucus per CP, g)i/ BW, g × 100% (2)
All of the experiments were conducted with three slugs that were not used in any
experiments before.
Table 3. Composition of phosphate buffered saline (PBS).







3. Results and Discussion
3.1. Evaluation of the Influence of Powders on Nasal Residence Time
Because mucociliary clearance is strongly affected by the viscoelastic properties of
nasal secretions, rheological assessments are used to evaluate the influence of the powders
on nasal residence time. Mucus is typically considered to be a viscoelastic fluid [27]. As
such, viscosity enables nasal mucus to sufficiently support a load, while elasticity restores
mucus to its original shape after deformation by the cilia. Elasticity was found to be the
most important for an efficient transport rate with an optimal elastic modulus of 1–2 Pa [30].
With a too-high elasticity, the mucus does not flow, while with a too-low elasticity, the
mucus does not move like a continuous sheet [27]. The selected mucoadhesive polymers
are expected to build up viscoelastic gels when they are in contact with the nasal fluid,
and thus to reduce the mucociliary clearance [10]. The selected fillers are not expected to
significantly increase the viscosity of SNF except for colloidal MCC, which is able to build
up colloidal gels after adequate dispersion through shearing. The steady shear viscosity of
the samples after 1 min and 15 min at a shear rate of 1 Hz is compared in Figure 2.
The two time points were assessed in order to simulate the change in viscosity from
the first contact of the sample with the moisture in the nose to the end of the residence time
at a physiological clearance rate. For the samples that show good dispersion and rapid
dissolution in SNF, a further increase of the initial viscosity with the progress of time and
swelling was expected, while for samples that are difficult to disperse in SNF, the solid
particles may lead to a high initial viscosity, which decreases when the gels become more
homogeneous. None of the samples showed a high increase of viscosity with the progress
of time; indeed, for HPMC, CMC and pectin, a decrease in viscosity was observed. As
observed visually, those samples rapidly build up highly-viscous areas around the polymer
particles, which influenced the measurements after 1 min, while after 15 min the gels were
more homogeneous. A rapid onset of gelling is required for nasal formulations to reduce
the mucociliary clearance rate directly after administration. Moreover, a rapid increase of
viscosity fixes the formulation to the original deposition site, which is required for targeted
drug delivery [31].
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The measurement of the steady shear viscosity was further used to quickly evaluate 
the influence of the particle size on the viscous behaviour of the polymer samples. On that 
point, no general statement can be made. While HPMC, HEC, and carboxymethyl chitosan 
show higher viscosity with smaller particles from 32–90 µm, HPC, CMC, and pectin show 
higher values with the larger particles from 90–150 µm. Hence, a broader particle size 
range from 32–150 µm was selected for the further experiments, in order to enable better 
comparability. The viscosity measurements of the fillers met the expectations for manni-
tol, lactose and MCC. For the colloidal MCC, it was not possible to build up a colloidal 
gel. Dissolved salts, such as those present in SNF, can inhibit the dispersion of colloidal 
Figure 2. (a, b) Particle size-dependent steady shear viscosity at 1 Hz of the mucoadhesive polymers (2% in SNF). The white
bars represent the sieve fraction (SF) 32–90 µm: light grey bars, SF 90–150 µm; dark grey bars, SF 32–150 µm. For better
visibility, the data is presented in two graphs with different scaling of the y-axis. (c) Steady shear viscosity at 1 Hz of the
fillers (SF 32–150 µm). (a–c) The plain bars show the steady shear viscosity after 1 min, and the striped bars after 15 min.
n = 3; error bars = sd.
The measurement of the steady shear viscosity was further used to quickly evaluate
the influence of the particle size on the viscous behaviour of the polymer samples. On
that point, no general statement can be made. While HPMC, HEC, and carboxymethyl
chitosan show higher viscosity with smaller particles from 32–90 µm, HPC, CMC, and
pectin show higher values with the larger particles from 90–150 µm. Hence, a broader
particle size range from 32–150 µm was selected for the further experiments, in order to
enable better comparability. The viscosity measurements of the fillers met the expectations
for mannitol, lactose and MCC. For the colloidal MCC, it was not possible to build up a
colloidal gel. Dissolved salts, such as those present in SNF, can inhibit the dispersion of
colloidal MCC, which contains an anionic component, and therefore prevent gelling [32].
In this regard, colloidal MCC is not advantageous over MCC in nasal powder delivery,
because a sufficient dispersion in the nose is not possible.
Oscillatory, strain-controlled measurements were conducted in order to assess the
viscoelastic properties of the gels formed by the mucoadhesive polymers after 1 min
and 15 min in SNF. The frequency-dependent elastic moduli (G′), viscous moduli (G”),
and the dissipation factors, which express the ratio between the viscous and the elastic
part of the viscoelastic deformation behaviour, are pictured in Figure 3. In oscillatory
frequency tests, the time-dependent deformation behaviour is examined, with frequency as
the inverse value of time. The short-term behaviour is simulated using rapid movements
(i.e. high frequencies), and the long-term behaviour is simulated with slow movements
(i.e., low frequencies).
Pharmaceutics 2021, 13, 385 8 of 14
Pharmaceutics 2021, 13, x 8 of 14 
 
 
MCC, which contains an anionic component, and therefore prevent gelling [32]. In this 
regard, colloidal MCC is not advantageous over MCC in nasal powder delivery, because 
a sufficient dispersion in the nose is not possible. 
Oscillatory, strain-controlled measurements were conducted in order to assess the 
viscoelastic properties of the gels formed by the mucoadhesive polymers after 1 min and 
15 min in SNF. The frequency-dependent elastic moduli (G′), viscous moduli (G″), and the 
dissipation factors, which express the ratio between the viscous and the elastic part of the 
viscoelastic deformation behaviour, are pictured in Figure 3. In oscillatory frequency tests, 
the time-dependent deformation behaviour is examined, with frequency as the inverse 
value of time. The short-term behaviour is simulated using rapid movements (i.e. high 




Figure 3. Frequency-dependent viscosity measurements of the mucoadhesive excipients: dotted 
lines with cross, elastic modulus (G′); solid lines with squares, viscous modulus (G′′); solid lines, 
dissipation factor (tan δ). (a) HPMC 400, HPC G, HEC G after 1 min resting time; (b) HPMC 4000, 
HPC M, HEC M after 1 min resting time; (c) CMC, Pectin, CM-Chitosan after 1 min resting time; 
(d) HPMC 400, HPC G, HEC G after 15 min resting time; (b) HPMC 4000, HPC M, HEC M after 15 
min resting time; (c) CMC, Pectin, CM-Chitosan after 15 min resting time. The mean of the meas-
urement of the three gels is shown; sd is not given for the clarity of the graph. 
The anionic polymers CMC and pectin show a gel character (G′ > G″) over the whole 
frequency range. Both materials immediately formed highly-viscous areas around the 
particles, which still existed after 15 min. The high values of the elastic modulus after 1 
(a3) 
Figure 3. Frequency-dependent viscosity measurements of the mucoadhesive excipients: dotted lines with cross, elastic
modulus (G′); solid lines with squares, viscous modulus (G′ ′); solid lines, dissipation factor (tan δ). (a) HPMC 400, HPC G,
HEC G after 1 min resting time; (b) HPMC 4000, HPC M, HE M after 1 min resting time; (c) CMC, Pectin, CM-Chitosan
after 1 min resting time; (d) HPMC 400, HPC G, HEC G af er 15 in resting time; (e) HPMC 4000, HPC M, HEC M after
15 min resting time; (f) CMC, Pectin, M-Chitosan after 15 min resting time. The mean of the measurement of the three gels
is shown; sd is not given for the clarity of the graph.
The anionic polymers CMC and pectin show a gel character (G′ > G”) over the
whole freque cy range. Both materials immediately formed highly-viscous areas around
the particles, which still existed after 15 min. The high values of the el tic mo ulus
after 1 min indicate tha mucociliary clearance would be strongly slowed down after
the first contact of the powder with nasal secretions, and that the formulation may stick
to its original site of deposition. The neutral polymers (HPMC, HPC, HEC) showed
sol character at low frequencies and gel character at higher frequencies. The point of
intersection (G′ = G”) occurred later for the shorter chain polymers (HPMC 400, HPC G,
HEC G) than with the longer chain polymers (HPMC 4000, HPC M, HEC M). The longer
chains are inflexible when they move rapidly, and are more likely to get entangled. Because
interpenetration and entanglement are assumed to be crucial steps in the consolidation state
of mucoadhesion [33], a high tendency to entanglement may be regarded as advantageous
for excipients for nasal powder formulations. Carboxymethyl chitosan behaved similarly
to the shorter-chain neutral polymers, with relatively low values for the elastic and viscous
moduli. All of the polymers formed gels after one minute in SNF that had values greater
than 1 Pa for the elastic modulus at 1 Hz. Hence, it can be assumed that all of the polymers
will slow down the mucociliary clearance rate directly after administration to the nasal
cavity. After 15 min, the viscous moduli became relatively higher, which is reflected in
the higher values of the dissipation factor, and indicates that the effect on the mucociliary
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clearance rate will decrease with time. After the drug is absorbed, a recovery of the
physiological clearance rate is needed to clear the insoluble components of the formulation
and to regain the physiological functionality of the nose; thus, a time-limited effect is
desirable. The duration of the effect may be controlled by the choice of polymer, and thus a
sufficient extension of nasal residence time for the drug absorption can be ensured.
Because the measuring of rheological properties is a rather artificial method which
does not mimic the actual conditions in the nose, in which the dry particles are deposited on
the surface of a moist mucosa, it is advisable to carry out a complementary method for the
characterisation of this contact stage. When dry polymer particles come into contact with
nasal mucosa, the polymer chains hydrate, while the surrounding mucosa dehydrates [34].
In order to reflect this wetting, the adhesion of dry polymer powders on agar–mucin
gels and pure agar gels was assessed. On pure agar gels, the extent and velocity of the
hydration can be examined. An increased adhesion on gels containing mucin indicates
specific interactions between the sample and the mucin that contribute to its mucoadhesive
properties. Figure 4 shows the displacement of the samples on an inclined plane of the gels.
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Focusing on the neutral polymers, it can be seen that the shorter chain polymers
moved expectedly faster than the longer chain polymers because of their lower viscosity
after wetting, and because of a minor tendency to entangle. HPC dislocated the slowest on
agar and ager-mucin gels of all of the neutral polymers, although the HPC gels did not show
the highest viscous and elastic moduli in the rheological assessments. A potential reason
for the earlier failure of the adhesive bonds of the other polymers is overhydration [33]. In
order to substantiate this theory, the dynamic vapour sorption of the samples was recorded.
It was found that HPC absorbed water vapour to a lesser extent than the other polymers,
which may result in more highly concentrated, and therefore more stable gels on the agar
plates. The results of the DVS measurements are summarised in Table 4. Carboxymethyl
chitosan showed a rapid displacement, comparable with the shorter chain neutral polymers,
which fits to its rheological properties. The displacement of the anionic polymers CMC
and pectin, however, could not be predicted from their viscoelastic properties. While CMC
showed little movement in the first two hours, and a later rapid displacement on both
agar and agar–mucin gels, pectin showed very rapid displacement on the agar gels, but
almost none on the agar–mucin gels. This result indicates a strong interaction of pectin
with the used mucin type II. The interactions of different types of pectin with mucin were
investigated in [35], and a high ability, especially of low methoxylated pectin, to engage in
hydrogen bonding with mucin was assumed. The relatively-rapid displacement of pectin
on agar gels, and of CMC, can be interpreted as adhesive failure because of overhydration
due to the very hygroscopic behaviour of the powders (see Table 4).
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Table 4. Dynamic vapor sorption: change in the mass of the polymers at 80% relative humidity in
the first cycle (n = 1).
Mucoadhesive Polymer Change in Mass—Ref, %at 80% P/P0
Hygroscopicity
HPMC 400 13.84 hygroscopic
HPMC 4000 14.14 hygroscopic
HPC G 12.17 hygroscopic
HPC M 12.09 hygroscopic
HEC G 25.87 very hygroscopic
HEC M 25.36 very hygroscopic
CMC 31.13 very hygroscopic
Pectin 23.42 very hygroscopic
Carboxymethyl Chitosan 97.70 deliquescent
Considering all of the results, the combination of the three methods was found to be
suitable for a screening of the excipients with regard on their decelerating effect on the
mucociliary clearance rate. Such an easy-to-use in vitro setup will be especially useful
as a screening tool in the phase of the development and optimisation of a formulation.
Other models, which are described in the literature for that purpose, are based on the
use of nasal tissues, such as rabbit, sheep, goat, calf, and pig mucosa [14]. In [15], a
wash-off technique is described, in which the formulation is spread onto the tissue and
the amount that remained on the tissue after a defined washing circle was quantified.
Another approach measures the required force to separate the formulation from the tissue
after a defined period of intimate contact [16]. Because the stickiness of a formulation on
nasal tissue does not necessarily match with its influence on ciliary movements, it cannot
be correlated with its effect on clearance in vivo. Hence, these methods are also mainly
useable as screening tools. However, tissues underlie interindividual differences, affecting
reproducibility. This bias may be propagated if the sample cannot be applied to the tissue
in a repeatable manner. When the tensile strength of adhesive bonds is assessed, a further
problem lies in the evaluation of the obtained results, because fracture can occur not only at
the interface between the mucosa and the sample but also within the sample or the mucus
layer [33]. Therefore, methods that enable a higher degree of standardisation, such as the
ones described in this study, are better suited for screening and quality testing.
The characteristics of mucoadhesive excipients will influence the residence time in
the nose to different extents, and they will also affect the absorption of active ingredients
(API) because hydrocolloidal matrices are formed upon the excipient hydration that the
API has to pass before absorption. In [5], the use of different types of HPC were found to be
beneficial for sumatriptan as a model drug with a high solubility and low permeability, but
not for warfarin, as model drug with an already-high permeability. Regarding that, a con-
clusive statement of the advantageousness of mucoadhesive excipients needs to consider
API properties. Therefore, in later stages of product development, further investigations
such as cell culture and in vivo experiments are inevitable. Absorption studies need to
be conducted in order to adjust and ensure the desired drug effect. Additionally, toxicity
assays are required in order to guaranty the safety of the formulation.
3.2. Evaluation of the Sensory Effects in the Nose
As described earlier, drug delivery via the nose requires the close contact of the
particles with the nasal tissue. This may cause irritation on the sensitive mucosa. The slug
mucosal irritation assay was used to screen the selected fillers and mucoadhesive agents
regarding their potential to cause stinging, itching and burning sensations. A correlation
between an increase in mucus production in slugs and an elevated incidence of these
sensations in humans was demonstrated in [21]; thus, the assay may serve as a surrogate
for clinical trials in early formulation development. The correlating mucus production of
slugs that were in contact with the powders is displayed in Figure 5.
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Figure 5. Total mucus production from three contact periods in the slug mucosal irritation assay, expressed as a percentage
of the initial bodyweight of the slugs. (a) Fillers; (b) mucoadhesive polymers. Unless otherwise stated, sieve fractions from
32–150 µm were used. The lines display the limit values for the different categories of nasal discomfort, as defined in [21]:
below the green line, no discomfort; below the yellow line, mild discomfort; below the red line, moderate discomfort; above
the red line, severe discomfort. n = 3, error bars = sd, * = p < 0.05, ** = p < 0.01.
All of the fillers significantly (p < 0.05) increased the mucus production of the slugs.
However, with the exception of mannitol with a mall parti le size, they are all within a
range which is not associated with disc mfort, according to [21]. Comparing the fillers, a
significantly higher mucus production was observed in slugs placed on mannitol than on
lactose. A potential reason would be the higher osmotic pressure that is caused by dissolved
mannitol particles. When soluble powder particles come into contact with moisture, like the
wet body wall of the slugs or the human nasal mucosa, increasingly concentrated solutions
are formed over time, which is accompanied by the increasing osmolarity of the respective
fluid. Because mannitol dissolves faster than lactose and has a lower molecular weight,
dissolving mannitol particles increase the osmolarity faster. Hyperosmolar solutions will
cause an efflux of water from the surrounding cells. Different studies already describe an
increased tendency for nasal irritation for hyperosmolar saline solutions when compared
with isotonic solutions, which is consistent with this theory [36,37]. However, the mucus
production observed for mannitol is not significantly higher than for the selected insoluble
fillers with the same particle size range. The influence of particle size was evaluated for
mannitol, and a significantly higher mucus production was found for the sieve fraction
32–90 µm than for the sieve fractions 32–150 µm or 90–150 µm. The obtained total mucus
production of 6.30 ± 0.61% of the initial body weight of the slugs indicates mild irritation
in the nose, possibly due to a faster dissolution of the smaller particles and hence a
more pronounced osmotic effect. Comparing the mucoadhesive excipients, carboxymethyl
chitosan stood out with a high total mucus production of 17.52± 0.63%, which is associated
with severe nasal discomfort, and ranges only slightly below benzalkonium chloride (BAC)
1% solution as positive control. The slugs tended to produce less mucus when they
were contact with the neutral polymers HPMC and HPC than when they were placed
on powders of the anionic polymers CMC and pectin. Contrary to this trend, the mucus
production was slightly higher in HEC, but the standard deviation was high, so there was
no statistically significant difference. For all of the other samples, results with quite small
variations were obtained, allowing a meaningful comparison of the different excipients.
Hence, the slug mucosal irritation assay is also a useful tool for the characterisation of
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powder formulations, and allows an early screening of formulations and excipients. Such
results are often difficult to obtain otherwise, because clinical trials are costly, and are often
used only at a later stage of development.
4. Conclusions
This work delivers a set of methods suitable for the assessment of excipients for nasal
powders and nasal powder formulations. Adhesiveness on agar–mucin plates, rheological
tests, and DVS measurements facilitate the meaningful characterisation of the samples, and
a combination of these methods is regarded as being valuable for the prediction of their
ability to enhance the residence time in the nasal cavity. Different mucoadhesive agents
were compared using the described methods. Assessing the rheological tests, all of the
samples are able to prolong the nasal residence time by increasing the elastic modulus at
1 Hz above 1 Pa. Longer polymer chains and an anionic charge were found to increase the
effect. HPC and pectin showed the strongest adhesion on agar–mucin gels, which can be
explained by a smaller extent of vapour sorption for HPC and specific interactions with
mucin for pectin. However, the attributes of the active ingredient have to be considered
in the interpretation of the data, and further investigations like cell culture and in vivo
experiments, focusing on the estimation of the drug absorption on the one hand and on
the evaluation of toxicity on the other hand, need to be conducted in the later phases of
product development. In order to deliver a tool to predict the sensory effects of nasal
powders, which come along with the close contact of particles and the mucosa, the slug
mucosal irritation assay was adopted for dry powders. The test permitted us to differentiate
between the samples with high reproducibility, and is therefore considered a suitable and
useful screening tool in nasal powder development. The screening of the different selected
fillers and mucoadhesive agents suggests the dependence of the nasal discomfort on the
particle size and the charge of the powder components.
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